Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLDXBearishResearch Analysisnews

High materiality9/10

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Aug 20, 2025, 10:41 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The failure to improve EoE symptoms after meeting primary endpoints is a significant setback. A similar situation is seen in companies like Incyte (INCY) when therapies do not yield clinical benefits, leading to stock declines.

AI summary

What happened, with direct paths to the underlying reporting

CLDX announced topline Phase 2 results for barzolvolimab in EoE. While the primary endpoint was met, EoE symptoms showed no improvement. Barzolvolimab has a favorable safety profile but will not advance in EoE. The stock dropped 11.12% following the announcement to $21.35. CLDX remains focused on other indications for barzolvolimab.

CLDX announced topline Phase 2 results for barzolvolimab in EoE.
While the primary endpoint was met, EoE symptoms showed no improvement.
Barzolvolimab has a favorable safety profile but will not advance in EoE.
The stock dropped 11.12% following the announcement to $21.35.
CLDX remains focused on other indications for barzolvolimab.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Celldex PN Phase 2 failure clouds barzolvolimab's CSU path